News und Analysen
Tenable Q2 Earnings Call Highlights
Key Points
- Interested in Tenable Holdings, Inc.? Here are five stocks we like better.
- Tenable exceeded Q2 guidance and raised its full-year outlook. Revenue rose 8.6% year over year to $268.5
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind’s Phase 1b trial met its short-term safety and tolerability objective in 27 IPF patients, with no
MiMedx Group Q2 Earnings Call Highlights
Key Points
- Interested in MiMedx Group, Inc? Here are five stocks we like better.
- MiMedx agreed to acquire Sanara MedTech for $35 per share, adding more than $100 million in surgical revenue and
Corcept Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Corcept Therapeutics Incorporated? Here are five stocks we like better.
- Second-quarter revenue rose 32% to $256.1 million, driven by growth in the Cushing’s syndrome
Align Technology Q2 Earnings Call Highlights
Key Points
- Interested in Align Technology, Inc.? Here are five stocks we like better.
- Record Q2 revenue reached $1.06 billion, up 4.3% year over year, driven by an 8.2% increase in clear
Crane Q2 Earnings Call Highlights
Key Points
- Interested in Crane? Here are five stocks we like better.
- Record Q2 performance: Crane reported 26% sales growth, 37% adjusted operating-profit growth and a record 21.3% adjusted
Europäische Kommission genehmigt Marktzulassung des an XFG angepassten COVID-19-Impfstoffs von Pfizer und BioNTech in der Europäischen Union
- Daten zeigten, dass die COVID-19-Impfstoffformulierung für das Jahr 2026-2027, die gegen die XFG-Variante gerichtet ist, eine starke Immunantwort gegen derzeit zirkulierende und neu auftretende
Chemed Q2 Earnings Call Highlights
Key Points
- Interested in Chemed Corporation? Here are five stocks we like better.
- Chemed delivered strong Q2 results: Consolidated revenue increased 8.8% year over year, adjusted diluted EPS
Boston Scientific Q2 Earnings Call Highlights
Key Points
- Interested in Boston Scientific Corporation? Here are five stocks we like better.
- Strong Q2 results, lower outlook: Boston Scientific posted 7% organic revenue growth and adjusted EPS
Bausch + Lomb Q2 Earnings Call Highlights
Key Points
- Interested in Bausch + Lomb Corporation? Here are five stocks we like better.
- Bausch + Lomb reported strong second-quarter results, with revenue up 8% year over year on a
D-Wave Quantum Aktie: AT&T beschleunigt Netzwerkoptimierung 240-fach
Ein Wechsel an die Nasdaq soll normalerweise Aufbruchsstimmung erzeugen. Bei D-Wave Quantum passiert genau…
Der Beitrag D-Wave Quantum Aktie: AT&T beschleunigt Netzwerkoptimierung 240-fach erschien
GE HealthCare Technologies Q2 Earnings Call Highlights
Key Points
- Interested in GE HealthCare Technologies Inc.? Here are five stocks we like better.
- GE HealthCare delivered solid underlying demand in Q2: Orders rose 11% year over year, backlog
Integra LifeSciences Q2 Earnings Call Highlights
Key Points
- Interested in Integra LifeSciences Holdings Corporation? Here are five stocks we like better.
- Q2 results exceeded expectations: Revenue rose 0.8% to $419 million, while adjusted EPS
Biogen Q2 Earnings Call Highlights
Key Points
- Interested in Biogen Inc.? Here are five stocks we like better.
- Biogen’s second-quarter revenue rose 3% to $2.7 billion, driven by growth products and the newly acquired Apellis
AxoGen Q2 Earnings Call Highlights
Key Points
- Interested in AxoGen, Inc.? Here are five stocks we like better.
- Strong revenue growth: AxoGen’s second-quarter revenue rose 23.1% year over year to $69.7 million, driven largely by
Anika Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Anika Therapeutics Inc.? Here are five stocks we like better.
- Second-quarter performance strengthened: Revenue rose 16% year over year to $32.6 million, while gross
Meridian Q2 Earnings Call Highlights
Key Points
- Interested in Meridian Holdings Inc.? Here are five stocks we like better.
- Meridian delivered stronger financial results: Second-quarter revenue rose 16% year over year to $50.2
Amarin Q2 Earnings Call Highlights
Key Points
- Interested in Amarin Corporation PLC? Here are five stocks we like better.
- International demand strengthened: Global in-market VASCEPA demand rose 59% year over year, while European
EQS-News: Dr. Sven K. Weber tritt Nachfolge von Adriaan Moelker als Vorstandsvorsitzender der BRAIN Biotech AG an
EQS-News: Dr. Sven K. Weber tritt Nachfolge von Adriaan Moelker als Vorstandsvorsitzender der BRAIN Biotech AG an
EQS-Adhoc: BRAIN Biotech AG bestellt Dr. Sven K. Weber zum 01. Oktober 2026 als neuen Vorsitzenden des Vorstands
EQS-Adhoc: BRAIN Biotech AG bestellt Dr. Sven K. Weber zum 01. Oktober 2026 als neuen Vorsitzenden des Vorstands
Intellia Therapeutics Aktie: lonvo-z vor Zulassungsantrag 2026
Intellia Therapeutics nähert sich einem kritischen Wendepunkt. Bei einem aktuellen Kurs von 9,57 Euro…
Der Beitrag Intellia Therapeutics Aktie: lonvo-z vor Zulassungsantrag 2026 erschien zuerst auf
AbbVie Aktie: RINVOQ punktet doppelt
Zwei EU-Zulassungen an einem Tag — das gab es für AbbVie selten. Die Europäische…
Der Beitrag AbbVie Aktie: RINVOQ punktet doppelt erschien zuerst auf kapitalmarktexperten.de.
Quelle kapitalmarktexp
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 30 Mio. für die Phase-3-Entwicklung des neuen Antipilzmittels Fosmanogepix
Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 29. Juli 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel
EQS-News: Gerresheimer veräußert Centor und das globale Primary Packaging Plastics Geschäft an Apax Fonds
EQS-News: Gerresheimer veräußert Centor und das globale Primary Packaging Plastics Geschäft an Apax Fonds
EQS-Adhoc: Gerresheimer veräußert Centor und das globale Primary Packaging Plastics Geschäft an Apax Fonds
EQS-Adhoc: Gerresheimer veräußert Centor und das globale Primary Packaging Plastics Geschäft an Apax Fonds